|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.010 USD | -5.05% |
|
-17.08% | +9.45% |
| 08/07 | Perspective Therapeutics, Inc. Announces Executive Changes | CI |
| 08/07 | Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-Founder Michael Schultz Moves to Advisory Role | MT |
Company Valuation: Perspective Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55.03 | 35.12 | 112.8 | 215.6 | 204.4 | 343.3 | - | - |
| Change | - | -36.19% | 221.19% | 91.16% | -5.18% | 67.92% | - | - |
| Enterprise Value (EV) 1 | 55.03 | 35.12 | 112.8 | -8.207 | 61.26 | 156.2 | 30.97 | 156.6 |
| Change | - | -36.19% | 221.19% | -107.28% | 846.48% | 154.9% | -80.16% | 405.64% |
| P/E | -12.9x | -4.94x | -2.36x | -2.59x | -1.96x | -2.71x | -2.66x | -2.82x |
| PBR | - | - | - | 0.78x | 0.99x | 1.34x | 1.14x | 1.6x |
| PEG | - | -0.1x | -0x | 0.1x | -0.1x | 0.1x | -1.22x | 0.48x |
| Capitalization / Revenue | 5.47x | 9.89x | 78.7x | 148x | 231x | 822x | 704x | 25.5x |
| EV / Revenue | 5.47x | 9.89x | 78.7x | -5.64x | 69.3x | 374x | 63.5x | 11.6x |
| EV / EBITDA | -19.1x | - | - | 0.13x | -0.56x | -1.23x | -0.21x | -1.02x |
| EV / EBIT | -16x | - | -2.75x | 0.12x | -0.54x | -1.24x | -0.21x | -1.08x |
| EV / FCF | - | - | -2.97x | 0.11x | -0.64x | -1.5x | -0.22x | -1.04x |
| FCF Yield | - | - | -33.7% | 886% | -155% | -66.8% | -448% | -96% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3 | -0.5 | -1.7 | -1.23 | -1.4 | -1.109 | -1.134 | -1.066 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10.05 | 3.552 | 1.434 | 1.454 | 0.884 | 0.4177 | 0.4875 | 13.49 |
| EBITDA 1 | -2.874 | - | - | -64.49 | -110.3 | -126.9 | -144.2 | -153 |
| EBIT 1 | -3.446 | - | -40.94 | -66.8 | -113.6 | -125.4 | -144.8 | -144.5 |
| Net income 1 | -3.39 | - | -46.51 | -79.28 | -103.1 | -121 | -138.1 | -137 |
| Net Debt 1 | - | - | - | -223.8 | -143.2 | -187.1 | -312.3 | -186.7 |
| Reference price 2 | 3.878 | 2.471 | 4.020 | 3.190 | 2.750 | 3.010 | 3.010 | 3.010 |
| Nbr of stocks (in thousands) | 14,192 | 14,211 | 28,057 | 67,588 | 74,338 | 1,14,046 | - | - |
| Announcement Date | 21/09/21 | 01/05/23 | 28/03/24 | 26/03/25 | 16/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.71x | 373.82x | -1.23x | -.--% | 34Cr | |
| 35.38x | 6.18x | 19.12x | 0.93% | 5.07TCr | |
| -23.4x | 342.07x | -22.1x | -.--% | 3.97TCr | |
| 25.29x | 2.8x | 12.09x | -.--% | 3.47TCr | |
| 45.73x | 4.51x | 28.9x | -.--% | 3.32TCr | |
| 27.05x | 7.93x | 19.91x | 0.42% | 2.68TCr | |
| 31.75x | 5.12x | 23.32x | -.--% | 1.54TCr | |
| 23.95x | 2.04x | 8.96x | 1.12% | 1.38TCr | |
| 23.74x | 1.89x | 11.45x | -.--% | 1.28TCr | |
| Average | 20.75x | 82.93x | 11.16x | 0.27% | 2.53TCr | |
| Weighted average by Cap. | 22.45x | 64.29x | 11.57x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CATX Stock
- Valuation Perspective Therapeutics, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
